Exostosin-1/exostosin-2 expression and favorable kidney outcomes in lupus nephritis: a retrospective cohort study

Introduction/Objectives The heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus erythematosus. This study aimed to evaluate the association between EXO-1/2 positivity in kidney biopsy and kidney outcomes. Methods The kidn...

Full description

Saved in:
Bibliographic Details
Published inClinical rheumatology Vol. 43; no. 8; pp. 2533 - 2540
Main Authors Zavala-Miranda, Maria Fernanda, Sobrino-Vargas, Ana María, Hernández-Andrade, Adriana, Caballero-Malacara, Valeria, Pérez-Arias, Abril A., Márquez-Macedo, Sofía E., Nordmann-Gomes, Alberto, Navarro-Sánchez, Valeria, Juárez-Cuevas, Bernardo, Uribe-Uribe, Norma O., Mejia-Vilet, Juan M.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.08.2024
Springer Nature B.V
Subjects
Antigens
Autoimmune diseases
Biopsy
blood serum
class
Clinical medicine
cohort studies
Creatinine
Epidermal growth factor receptors
Glomerular filtration rate
histology
Kidney diseases
kidneys
Lupus
lupus erythematosus
Lupus nephritis
Medicine
Medicine & Public Health
Membranous nephropathy
nephritis
Nephropathy
Original Article
Prognosis
Renal failure
Rheumatology
Statistical analysis
Systemic lupus erythematosus
Exostosin
Erythematosus
Prognosis
Lupus nephritis
Membranous nephropathy
Systemic lupus
Online AccessGet full text

Cover

Abstract Introduction/Objectives The heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus erythematosus. This study aimed to evaluate the association between EXO-1/2 positivity in kidney biopsy and kidney outcomes. Methods The kidney biopsy tissue from 50 class 5 lupus nephritis (LN) and 55 mixed class 3/4 + 5 LN patients was stained for EXO-1/2. Baseline clinical and histological characteristics were compared between EXO-1/2 positive and EXO-1/2 negative patients. Time-to-event analyses were performed to compare rates of response to therapy, kidney flares, and progression to a 40% decline of the glomerular filtration rate (eGFR), doubling of serum creatinine, and kidney failure. Results Fourteen out of 50 (28%) of class 5 and 5 out of 55 (9%) of mixed class 3/4 + 5 LN stained positive for EXO-1/2. Patients with class 5 LN and EXO-1/2 positive stain were younger, with better kidney function at presentation, and lower scarring in the kidney biopsy analysis. Over a median follow-up of 100 months, patients with positive EXO-1/2 staining had significantly lower rates of progression in the full cohort. When analyzed separately in class 5 and mixed class LN subgroups, there were significantly lower rates of progression to a 40% decline of the eGFR and non-statistically significant trends for doubling of serum creatinine and kidney failure. Conclusion EXO-1/2 is a novel antigen detected in class 5 LN and associated with a good prognosis of kidney function. The incorporation of EXO-1/2 staining in clinical practice can potentially modify the management of LN due to its prognostic implications. Key Points • Exostosin-1/exostosin-2 antigen has been found in cases of membranous nephropathy associated with autoimmune diseases such as systemic lupus erythematosus. • Exostosin-1/exostosin-2 staining in the kidney biopsy of class 5 or mixed class 3/4  +  5 lupus nephritis is associated with a good long-term prognosis of kidney function. • The incorporation of exostosin-1/exostosin-2 staining into clinical practice can potentially modify management due to its prognostic implications.
AbstractList Introduction/Objectives The heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus erythematosus. This study aimed to evaluate the association between EXO-1/2 positivity in kidney biopsy and kidney outcomes. Methods The kidney biopsy tissue from 50 class 5 lupus nephritis (LN) and 55 mixed class 3/4 + 5 LN patients was stained for EXO-1/2. Baseline clinical and histological characteristics were compared between EXO-1/2 positive and EXO-1/2 negative patients. Time-to-event analyses were performed to compare rates of response to therapy, kidney flares, and progression to a 40% decline of the glomerular filtration rate (eGFR), doubling of serum creatinine, and kidney failure. Results Fourteen out of 50 (28%) of class 5 and 5 out of 55 (9%) of mixed class 3/4 + 5 LN stained positive for EXO-1/2. Patients with class 5 LN and EXO-1/2 positive stain were younger, with better kidney function at presentation, and lower scarring in the kidney biopsy analysis. Over a median follow-up of 100 months, patients with positive EXO-1/2 staining had significantly lower rates of progression in the full cohort. When analyzed separately in class 5 and mixed class LN subgroups, there were significantly lower rates of progression to a 40% decline of the eGFR and non-statistically significant trends for doubling of serum creatinine and kidney failure. Conclusion EXO-1/2 is a novel antigen detected in class 5 LN and associated with a good prognosis of kidney function. The incorporation of EXO-1/2 staining in clinical practice can potentially modify the management of LN due to its prognostic implications. Key Points • Exostosin-1/exostosin-2 antigen has been found in cases of membranous nephropathy associated with autoimmune diseases such as systemic lupus erythematosus. • Exostosin-1/exostosin-2 staining in the kidney biopsy of class 5 or mixed class 3/4  +  5 lupus nephritis is associated with a good long-term prognosis of kidney function. • The incorporation of exostosin-1/exostosin-2 staining into clinical practice can potentially modify management due to its prognostic implications.
The heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus erythematosus. This study aimed to evaluate the association between EXO-1/2 positivity in kidney biopsy and kidney outcomes. The kidney biopsy tissue from 50 class 5 lupus nephritis (LN) and 55 mixed class 3/4 + 5 LN patients was stained for EXO-1/2. Baseline clinical and histological characteristics were compared between EXO-1/2 positive and EXO-1/2 negative patients. Time-to-event analyses were performed to compare rates of response to therapy, kidney flares, and progression to a 40% decline of the glomerular filtration rate (eGFR), doubling of serum creatinine, and kidney failure. Fourteen out of 50 (28%) of class 5 and 5 out of 55 (9%) of mixed class 3/4 + 5 LN stained positive for EXO-1/2. Patients with class 5 LN and EXO-1/2 positive stain were younger, with better kidney function at presentation, and lower scarring in the kidney biopsy analysis. Over a median follow-up of 100 months, patients with positive EXO-1/2 staining had significantly lower rates of progression in the full cohort. When analyzed separately in class 5 and mixed class LN subgroups, there were significantly lower rates of progression to a 40% decline of the eGFR and non-statistically significant trends for doubling of serum creatinine and kidney failure. EXO-1/2 is a novel antigen detected in class 5 LN and associated with a good prognosis of kidney function. The incorporation of EXO-1/2 staining in clinical practice can potentially modify the management of LN due to its prognostic implications. Key Points • Exostosin-1/exostosin-2 antigen has been found in cases of membranous nephropathy associated with autoimmune diseases such as systemic lupus erythematosus. • Exostosin-1/exostosin-2 staining in the kidney biopsy of class 5 or mixed class 3/4 + 5 lupus nephritis is associated with a good long-term prognosis of kidney function. • The incorporation of exostosin-1/exostosin-2 staining into clinical practice can potentially modify management due to its prognostic implications.
Introduction/ObjectivesThe heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus erythematosus. This study aimed to evaluate the association between EXO-1/2 positivity in kidney biopsy and kidney outcomes.MethodsThe kidney biopsy tissue from 50 class 5 lupus nephritis (LN) and 55 mixed class 3/4 + 5 LN patients was stained for EXO-1/2. Baseline clinical and histological characteristics were compared between EXO-1/2 positive and EXO-1/2 negative patients. Time-to-event analyses were performed to compare rates of response to therapy, kidney flares, and progression to a 40% decline of the glomerular filtration rate (eGFR), doubling of serum creatinine, and kidney failure.ResultsFourteen out of 50 (28%) of class 5 and 5 out of 55 (9%) of mixed class 3/4 + 5 LN stained positive for EXO-1/2. Patients with class 5 LN and EXO-1/2 positive stain were younger, with better kidney function at presentation, and lower scarring in the kidney biopsy analysis. Over a median follow-up of 100 months, patients with positive EXO-1/2 staining had significantly lower rates of progression in the full cohort. When analyzed separately in class 5 and mixed class LN subgroups, there were significantly lower rates of progression to a 40% decline of the eGFR and non-statistically significant trends for doubling of serum creatinine and kidney failure.ConclusionEXO-1/2 is a novel antigen detected in class 5 LN and associated with a good prognosis of kidney function. The incorporation of EXO-1/2 staining in clinical practice can potentially modify the management of LN due to its prognostic implications. Key Points• Exostosin-1/exostosin-2 antigen has been found in cases of membranous nephropathy associated with autoimmune diseases such as systemic lupus erythematosus.• Exostosin-1/exostosin-2 staining in the kidney biopsy of class 5 or mixed class 3/4 + 5 lupus nephritis is associated with a good long-term prognosis of kidney function.• The incorporation of exostosin-1/exostosin-2 staining into clinical practice can potentially modify management due to its prognostic implications.
INTRODUCTION/OBJECTIVES: The heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus erythematosus. This study aimed to evaluate the association between EXO-1/2 positivity in kidney biopsy and kidney outcomes. METHODS: The kidney biopsy tissue from 50 class 5 lupus nephritis (LN) and 55 mixed class 3/4 + 5 LN patients was stained for EXO-1/2. Baseline clinical and histological characteristics were compared between EXO-1/2 positive and EXO-1/2 negative patients. Time-to-event analyses were performed to compare rates of response to therapy, kidney flares, and progression to a 40% decline of the glomerular filtration rate (eGFR), doubling of serum creatinine, and kidney failure. RESULTS: Fourteen out of 50 (28%) of class 5 and 5 out of 55 (9%) of mixed class 3/4 + 5 LN stained positive for EXO-1/2. Patients with class 5 LN and EXO-1/2 positive stain were younger, with better kidney function at presentation, and lower scarring in the kidney biopsy analysis. Over a median follow-up of 100 months, patients with positive EXO-1/2 staining had significantly lower rates of progression in the full cohort. When analyzed separately in class 5 and mixed class LN subgroups, there were significantly lower rates of progression to a 40% decline of the eGFR and non-statistically significant trends for doubling of serum creatinine and kidney failure. CONCLUSION: EXO-1/2 is a novel antigen detected in class 5 LN and associated with a good prognosis of kidney function. The incorporation of EXO-1/2 staining in clinical practice can potentially modify the management of LN due to its prognostic implications. Key Points • Exostosin-1/exostosin-2 antigen has been found in cases of membranous nephropathy associated with autoimmune diseases such as systemic lupus erythematosus. • Exostosin-1/exostosin-2 staining in the kidney biopsy of class 5 or mixed class 3/4 + 5 lupus nephritis is associated with a good long-term prognosis of kidney function. • The incorporation of exostosin-1/exostosin-2 staining into clinical practice can potentially modify management due to its prognostic implications.
The heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus erythematosus. This study aimed to evaluate the association between EXO-1/2 positivity in kidney biopsy and kidney outcomes.INTRODUCTION/OBJECTIVESThe heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus erythematosus. This study aimed to evaluate the association between EXO-1/2 positivity in kidney biopsy and kidney outcomes.The kidney biopsy tissue from 50 class 5 lupus nephritis (LN) and 55 mixed class 3/4 + 5 LN patients was stained for EXO-1/2. Baseline clinical and histological characteristics were compared between EXO-1/2 positive and EXO-1/2 negative patients. Time-to-event analyses were performed to compare rates of response to therapy, kidney flares, and progression to a 40% decline of the glomerular filtration rate (eGFR), doubling of serum creatinine, and kidney failure.METHODSThe kidney biopsy tissue from 50 class 5 lupus nephritis (LN) and 55 mixed class 3/4 + 5 LN patients was stained for EXO-1/2. Baseline clinical and histological characteristics were compared between EXO-1/2 positive and EXO-1/2 negative patients. Time-to-event analyses were performed to compare rates of response to therapy, kidney flares, and progression to a 40% decline of the glomerular filtration rate (eGFR), doubling of serum creatinine, and kidney failure.Fourteen out of 50 (28%) of class 5 and 5 out of 55 (9%) of mixed class 3/4 + 5 LN stained positive for EXO-1/2. Patients with class 5 LN and EXO-1/2 positive stain were younger, with better kidney function at presentation, and lower scarring in the kidney biopsy analysis. Over a median follow-up of 100 months, patients with positive EXO-1/2 staining had significantly lower rates of progression in the full cohort. When analyzed separately in class 5 and mixed class LN subgroups, there were significantly lower rates of progression to a 40% decline of the eGFR and non-statistically significant trends for doubling of serum creatinine and kidney failure.RESULTSFourteen out of 50 (28%) of class 5 and 5 out of 55 (9%) of mixed class 3/4 + 5 LN stained positive for EXO-1/2. Patients with class 5 LN and EXO-1/2 positive stain were younger, with better kidney function at presentation, and lower scarring in the kidney biopsy analysis. Over a median follow-up of 100 months, patients with positive EXO-1/2 staining had significantly lower rates of progression in the full cohort. When analyzed separately in class 5 and mixed class LN subgroups, there were significantly lower rates of progression to a 40% decline of the eGFR and non-statistically significant trends for doubling of serum creatinine and kidney failure.EXO-1/2 is a novel antigen detected in class 5 LN and associated with a good prognosis of kidney function. The incorporation of EXO-1/2 staining in clinical practice can potentially modify the management of LN due to its prognostic implications. Key Points • Exostosin-1/exostosin-2 antigen has been found in cases of membranous nephropathy associated with autoimmune diseases such as systemic lupus erythematosus. • Exostosin-1/exostosin-2 staining in the kidney biopsy of class 5 or mixed class 3/4 + 5 lupus nephritis is associated with a good long-term prognosis of kidney function. • The incorporation of exostosin-1/exostosin-2 staining into clinical practice can potentially modify management due to its prognostic implications.CONCLUSIONEXO-1/2 is a novel antigen detected in class 5 LN and associated with a good prognosis of kidney function. The incorporation of EXO-1/2 staining in clinical practice can potentially modify the management of LN due to its prognostic implications. Key Points • Exostosin-1/exostosin-2 antigen has been found in cases of membranous nephropathy associated with autoimmune diseases such as systemic lupus erythematosus. • Exostosin-1/exostosin-2 staining in the kidney biopsy of class 5 or mixed class 3/4 + 5 lupus nephritis is associated with a good long-term prognosis of kidney function. • The incorporation of exostosin-1/exostosin-2 staining into clinical practice can potentially modify management due to its prognostic implications.
Author Hernández-Andrade, Adriana
Navarro-Sánchez, Valeria
Caballero-Malacara, Valeria
Márquez-Macedo, Sofía E.
Nordmann-Gomes, Alberto
Sobrino-Vargas, Ana María
Pérez-Arias, Abril A.
Uribe-Uribe, Norma O.
Mejia-Vilet, Juan M.
Juárez-Cuevas, Bernardo
Zavala-Miranda, Maria Fernanda
Author_xml – sequence: 1
  givenname: Maria Fernanda
  orcidid: 0009-0006-9072-6957
  surname: Zavala-Miranda
  fullname: Zavala-Miranda, Maria Fernanda
  organization: Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
– sequence: 2
  givenname: Ana María
  orcidid: 0009-0003-3663-8583
  surname: Sobrino-Vargas
  fullname: Sobrino-Vargas, Ana María
  organization: Department of Pathology and Anatomic Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
– sequence: 3
  givenname: Adriana
  orcidid: 0009-0009-8566-0094
  surname: Hernández-Andrade
  fullname: Hernández-Andrade, Adriana
  organization: Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
– sequence: 4
  givenname: Valeria
  surname: Caballero-Malacara
  fullname: Caballero-Malacara, Valeria
  organization: Department of Pathology and Anatomic Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
– sequence: 5
  givenname: Abril A.
  orcidid: 0000-0001-6537-3666
  surname: Pérez-Arias
  fullname: Pérez-Arias, Abril A.
  organization: Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
– sequence: 6
  givenname: Sofía E.
  orcidid: 0000-0002-6718-1884
  surname: Márquez-Macedo
  fullname: Márquez-Macedo, Sofía E.
  organization: Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
– sequence: 7
  givenname: Alberto
  orcidid: 0009-0008-9763-8209
  surname: Nordmann-Gomes
  fullname: Nordmann-Gomes, Alberto
  organization: Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
– sequence: 8
  givenname: Valeria
  orcidid: 0009-0000-2203-9430
  surname: Navarro-Sánchez
  fullname: Navarro-Sánchez, Valeria
  organization: Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
– sequence: 9
  givenname: Bernardo
  orcidid: 0009-0005-3406-5448
  surname: Juárez-Cuevas
  fullname: Juárez-Cuevas, Bernardo
  organization: Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
– sequence: 10
  givenname: Norma O.
  orcidid: 0000-0002-4429-1298
  surname: Uribe-Uribe
  fullname: Uribe-Uribe, Norma O.
  organization: Department of Pathology and Anatomic Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
– sequence: 11
  givenname: Juan M.
  orcidid: 0000-0003-4062-9412
  surname: Mejia-Vilet
  fullname: Mejia-Vilet, Juan M.
  email: juan.mejiav@incmnsz.mx
  organization: Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38922553$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1v1DAQhi1URLeFP8ABWeLCxdTjjyTmhqpCK1XiAufISSbUJWunnqTa_fc1bCkSB7h4fHjeGc08J-wopoiMvQb5HqSsz6i8VS2kMkLW0mixe8Y2YLQRzhl3xDayrqXQ4JpjdkJ0K6VUjYMX7Fg3Tilr9YbdXewSLYlCFHCGT3_FcTdnJAopch8HPvr7lH03If8Rhoh7ntalT1skHiKf1nklHnG-yWEJ9IF7nnHJiWbsl3CPvE83KS-clnXYv2TPRz8Rvnqsp-zbp4uv55fi-svnq_OP16LX1i1icHKsrBqtsfUAtunAjKABOjn4Thk_SqsVKOOcdqh803d9XyuvGhhLHTp9yt4d-s453a1IS7sN1OM0-YhppVaD1TVApav_o7JWylXa6oK-_Qu9TWuOZZFCNaYYAWgK9eaRWrstDu2cw9bnffv77gVQB6AvV6KM4xMCsv0ptz3IbYvc9pfcdldC-hCiAsfvmP_M_kfqAf5Sp2A
Cites_doi 10.1016/j.ekir.2021.04.025
10.1007/s40620-023-01779-6
10.1016/j.reuma.2017.04.005
10.1093/rheumatology/keac407
10.1093/ndt/gfs073
10.1002/art.39594
10.1681/ASN.2018080852
10.1111/j.1523-1755.2004.00443.x
10.1177/09612033231225345
10.1093/ndt/gfad227
10.1038/nature05817
10.1681/ASN.2007080842
10.1681/ASN.2020081181
10.1002/art.40930
10.1016/j.ekir.2022.07.164
10.2215/CJN.00350122
10.1038/ki.2014.115
10.1038/s41572-019-0141-9
10.1016/j.kint.2017.11.023
10.1093/ndt/gfac058
10.1136/lupus-2023-001051
ContentType Journal Article
Copyright The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Copyright_xml – notice: The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
DBID AAYXX
CITATION
NPM
3V.
7T5
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
7S9
L.6
DOI 10.1007/s10067-024-07043-x
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
PubMed
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList
PubMed
ProQuest One Academic Middle East (New)
AGRICOLA
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1434-9949
EndPage 2540
ExternalDocumentID 38922553
10_1007_s10067_024_07043_x
Genre Journal Article
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
199
1N0
1SB
203
28-
29B
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5RE
5VS
67Z
6NX
78A
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LLZTM
M1P
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
YLTOR
Z45
Z7U
Z82
Z83
Z87
Z8O
Z8V
Z91
ZGI
ZMTXR
ZOVNA
~A9
~EX
~KM
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
NPM
7T5
7XB
8FK
ABRTQ
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
PUEGO
7X8
7S9
L.6
ID FETCH-LOGICAL-c359t-d90f652f5457d158b14f1311b0dab24af05321249939e2a8cbcc72a281fc72db3
IEDL.DBID 7X7
ISSN 0770-3198
1434-9949
IngestDate Fri Jul 11 01:23:48 EDT 2025
Sun Aug 24 03:22:57 EDT 2025
Sat Aug 23 14:25:57 EDT 2025
Thu Apr 03 07:08:22 EDT 2025
Tue Jul 01 04:05:24 EDT 2025
Fri Feb 21 02:40:08 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Exostosin
Erythematosus
Prognosis
Lupus nephritis
Membranous nephropathy
Systemic lupus
Language English
License 2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c359t-d90f652f5457d158b14f1311b0dab24af05321249939e2a8cbcc72a281fc72db3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-6718-1884
0009-0006-9072-6957
0009-0008-9763-8209
0009-0009-8566-0094
0009-0005-3406-5448
0000-0003-4062-9412
0009-0003-3663-8583
0000-0002-4429-1298
0000-0001-6537-3666
0009-0000-2203-9430
PMID 38922553
PQID 3084100118
PQPubID 326351
PageCount 8
ParticipantIDs proquest_miscellaneous_3153711636
proquest_miscellaneous_3072296353
proquest_journals_3084100118
pubmed_primary_38922553
crossref_primary_10_1007_s10067_024_07043_x
springer_journals_10_1007_s10067_024_07043_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-08-01
PublicationDateYYYYMMDD 2024-08-01
PublicationDate_xml – month: 08
  year: 2024
  text: 2024-08-01
  day: 01
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: Germany
– name: Heidelberg
PublicationSubtitle Journal of the International League of Associations for Rheumatology
PublicationTitle Clinical rheumatology
PublicationTitleAbbrev Clin Rheumatol
PublicationTitleAlternate Clin Rheumatol
PublicationYear 2024
Publisher Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Springer International Publishing
– name: Springer Nature B.V
References Tektonidou, Dasgupta, Ward (CR4) 2016; 68
Silva-Fernández, Otón, Askanase (CR5) 2019; 15
Saïdi, Brochériou, Estève (CR10) 2021; 6
Bajema, Wilhelmus, Alpers (CR15) 2018; 93
Miller, Caza, Larsen, Charu (CR19) 2023; 38
Li, Lan, Yu (CR11) 2022; 7
Ravindran, Casal Moura, Fervenza (CR9) 2021; 32
Rops, Loeven, van Gemst (CR8) 2014; 86
Ye, Jiang, Zeng (CR12) 2023; 10
Zavala-Miranda, Perez-Arias, Márquez-Macedo (CR14) 2023; 62
Sethi, Madden, Debiec (CR16) 2019; 30
Yap, Tang, Ma (CR1) 2012; 27
Weening, D’Agati, Schwartz (CR3) 2004; 65
Wang, Liu, Zhang (CR18) 2022; 17
Hu, Zhu, Wang (CR6) 2024; 33
Sethi, Fervenza (CR7) 2023
Roberts, Gleadle (CR21) 2008; 19
Bishop, Schuksz, Esko (CR20) 2007; 446
Anders, Saxena, Zhao (CR2) 2020; 6
Liu, Wan, Cao (CR17) 2023; 37
Aringer, Costenbader, Daikh (CR13) 2019; 71
S Sethi (7043_CR7) 2023
JR Bishop (7043_CR20) 2007; 446
JJ Weening (7043_CR3) 2004; 65
L Silva-Fernández (7043_CR5) 2019; 15
AL Rops (7043_CR8) 2014; 86
J Hu (7043_CR6) 2024; 33
IM Bajema (7043_CR15) 2018; 93
MG Tektonidou (7043_CR4) 2016; 68
Z Liu (7043_CR17) 2023; 37
MF Zavala-Miranda (7043_CR14) 2023; 62
HJ Anders (7043_CR2) 2020; 6
A Ravindran (7043_CR9) 2021; 32
S Sethi (7043_CR16) 2019; 30
DYH Yap (7043_CR1) 2012; 27
PP Miller (7043_CR19) 2023; 38
M Saïdi (7043_CR10) 2021; 6
ISD Roberts (7043_CR21) 2008; 19
T Ye (7043_CR12) 2023; 10
C Wang (7043_CR18) 2022; 17
H Li (7043_CR11) 2022; 7
M Aringer (7043_CR13) 2019; 71
References_xml – volume: 6
  start-page: 1977
  year: 2021
  end-page: 1980
  ident: CR10
  article-title: The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets with Different Outcomes
  publication-title: Kidney Int Rep
  doi: 10.1016/j.ekir.2021.04.025
– volume: 37
  start-page: 149
  year: 2023
  end-page: 158
  ident: CR17
  article-title: Distribution spectrum and clinical significance of glomerular exostosin (EXT1) deposits in PLA2R-positive membranous nephropathy
  publication-title: J Nephrol
  doi: 10.1007/s40620-023-01779-6
– volume: 15
  start-page: 34
  year: 2019
  end-page: 42
  ident: CR5
  article-title: Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature
  publication-title: Reumatol Clin
  doi: 10.1016/j.reuma.2017.04.005
– volume: 62
  start-page: 1136
  year: 2023
  end-page: 1144
  ident: CR14
  article-title: Characteristics and outcomes of a Hispanic lupus nephritis cohort from Mexico
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/keac407
– volume: 27
  start-page: 3248
  year: 2012
  end-page: 3254
  ident: CR1
  article-title: Survival analysis and causes of mortality in patients with lupus nephritis
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfs073
– volume: 68
  start-page: 1432
  year: 2016
  end-page: 1441
  ident: CR4
  article-title: Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971–2015: A Systematic Review and Bayesian Meta-Analysis
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.39594
– volume: 30
  start-page: 1123
  year: 2019
  end-page: 1136
  ident: CR16
  article-title: Exostosin 1/Exostosin 2–Associated Membranous Nephropathy
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2018080852
– volume: 65
  start-page: 521
  year: 2004
  end-page: 530
  ident: CR3
  article-title: The classification of glomerulonephritis in systemic lupus erythematosus revisited
  publication-title: Kidney Int
  doi: 10.1111/j.1523-1755.2004.00443.x
– volume: 33
  start-page: 192
  year: 2024
  end-page: 200
  ident: CR6
  article-title: The clinicopathological features and renal prognostic factors in pure membranous lupus nephritis—a large series cohort study from China
  publication-title: Lupus
  doi: 10.1177/09612033231225345
– year: 2023
  ident: CR7
  article-title: Membranous nephropathy—diagnosis and identification of target antigens
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfad227
– volume: 446
  start-page: 1030
  year: 2007
  end-page: 1037
  ident: CR20
  article-title: Heparan sulphate proteoglycans fine-tune mammalian physiology
  publication-title: Nature
  doi: 10.1038/nature05817
– volume: 19
  start-page: 450
  year: 2008
  end-page: 453
  ident: CR21
  article-title: Familial Nephropathy and Multiple Exostoses With Exostosin-1 (EXT1) Gene Mutation
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2007080842
– volume: 32
  start-page: 695
  year: 2021
  end-page: 706
  ident: CR9
  article-title: In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2020081181
– volume: 71
  start-page: 1400
  year: 2019
  end-page: 1412
  ident: CR13
  article-title: 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.40930
– volume: 7
  start-page: 2295
  year: 2022
  end-page: 2298
  ident: CR11
  article-title: Analysis of the Expression of Exostosins and Clinicopathological Features in Membranous Lupus Nephritis in a Chinese Cohort
  publication-title: Kidney Int Rep
  doi: 10.1016/j.ekir.2022.07.164
– volume: 17
  start-page: 986
  year: 2022
  end-page: 993
  ident: CR18
  article-title: Glomerular Exostosin as a Subtype and Activity Marker of Class 5 Lupus Nephritis
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.00350122
– volume: 86
  start-page: 932
  year: 2014
  end-page: 942
  ident: CR8
  article-title: Modulation of heparan sulfate in the glomerular endothelial glycocalyx decreases leukocyte influx during experimental glomerulonephritis
  publication-title: Kidney Int
  doi: 10.1038/ki.2014.115
– volume: 6
  start-page: 7
  year: 2020
  ident: CR2
  publication-title: Lupus nephritis Nat Rev Dis Primers
  doi: 10.1038/s41572-019-0141-9
– volume: 93
  start-page: 789
  year: 2018
  end-page: 796
  ident: CR15
  article-title: Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2017.11.023
– volume: 38
  start-page: 396
  year: 2023
  end-page: 404
  ident: CR19
  article-title: EXT1 and NCAM1-associated membranous lupus nephritis in a cohort of patients undergoing repeat kidney biopsies
  publication-title: Nephrol DialTransplant
  doi: 10.1093/ndt/gfac058
– volume: 10
  start-page: e001051
  year: 2023
  ident: CR12
  article-title: Clinical significance of exostosin 1 in confirmed and suspected lupus membranous nephropathy
  publication-title: Lupus Sci Med
  doi: 10.1136/lupus-2023-001051
– volume: 15
  start-page: 34
  year: 2019
  ident: 7043_CR5
  publication-title: Reumatol Clin
  doi: 10.1016/j.reuma.2017.04.005
– volume: 7
  start-page: 2295
  year: 2022
  ident: 7043_CR11
  publication-title: Kidney Int Rep
  doi: 10.1016/j.ekir.2022.07.164
– volume: 68
  start-page: 1432
  year: 2016
  ident: 7043_CR4
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.39594
– volume: 32
  start-page: 695
  year: 2021
  ident: 7043_CR9
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2020081181
– volume: 30
  start-page: 1123
  year: 2019
  ident: 7043_CR16
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2018080852
– volume: 17
  start-page: 986
  year: 2022
  ident: 7043_CR18
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.00350122
– volume: 6
  start-page: 7
  year: 2020
  ident: 7043_CR2
  publication-title: Lupus nephritis Nat Rev Dis Primers
  doi: 10.1038/s41572-019-0141-9
– year: 2023
  ident: 7043_CR7
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfad227
– volume: 62
  start-page: 1136
  year: 2023
  ident: 7043_CR14
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/keac407
– volume: 65
  start-page: 521
  year: 2004
  ident: 7043_CR3
  publication-title: Kidney Int
  doi: 10.1111/j.1523-1755.2004.00443.x
– volume: 38
  start-page: 396
  year: 2023
  ident: 7043_CR19
  publication-title: Nephrol DialTransplant
  doi: 10.1093/ndt/gfac058
– volume: 19
  start-page: 450
  year: 2008
  ident: 7043_CR21
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2007080842
– volume: 86
  start-page: 932
  year: 2014
  ident: 7043_CR8
  publication-title: Kidney Int
  doi: 10.1038/ki.2014.115
– volume: 93
  start-page: 789
  year: 2018
  ident: 7043_CR15
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2017.11.023
– volume: 446
  start-page: 1030
  year: 2007
  ident: 7043_CR20
  publication-title: Nature
  doi: 10.1038/nature05817
– volume: 6
  start-page: 1977
  year: 2021
  ident: 7043_CR10
  publication-title: Kidney Int Rep
  doi: 10.1016/j.ekir.2021.04.025
– volume: 27
  start-page: 3248
  year: 2012
  ident: 7043_CR1
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfs073
– volume: 10
  start-page: e001051
  year: 2023
  ident: 7043_CR12
  publication-title: Lupus Sci Med
  doi: 10.1136/lupus-2023-001051
– volume: 33
  start-page: 192
  year: 2024
  ident: 7043_CR6
  publication-title: Lupus
  doi: 10.1177/09612033231225345
– volume: 71
  start-page: 1400
  year: 2019
  ident: 7043_CR13
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.40930
– volume: 37
  start-page: 149
  year: 2023
  ident: 7043_CR17
  publication-title: J Nephrol
  doi: 10.1007/s40620-023-01779-6
SSID ssj0002891
Score 2.4035897
Snippet Introduction/Objectives The heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus...
The heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus erythematosus. This...
Introduction/ObjectivesThe heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus...
INTRODUCTION/OBJECTIVES: The heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 2533
SubjectTerms Antigens
Autoimmune diseases
Biopsy
blood serum
class
Clinical medicine
cohort studies
Creatinine
Epidermal growth factor receptors
Glomerular filtration rate
histology
Kidney diseases
kidneys
Lupus
lupus erythematosus
Lupus nephritis
Medicine
Medicine & Public Health
Membranous nephropathy
nephritis
Nephropathy
Original Article
Prognosis
Renal failure
Rheumatology
Statistical analysis
Systemic lupus erythematosus
SummonAdditionalLinks – databaseName: SpringerLink Journals (ICM)
  dbid: U2A
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bS8MwFA4yQXwR706nRPBNg82lN9-GbAxhPjnYW0nSFIYjm1sr89970rWbMhV8WmFpSc85_fKFk_MdhG6AsDGtg5RwoTkRvsqIFJ4kgeJCUU-GvCwU7j8HvYF4GvrDqihsXp92r1OSJVJ_KXYDZCWwphAIU8EJMMdt3-3dIYoHrL3CX1b1yQtDhzBxVJXK_PyM78vRBsfcyI-Wy053H-1VfBG3lw4-QFvGHqKdfpURP0JvnYWTxoAdP6H3ZnXNsFlUR1wtljbFmXwHZ6uxwa-j1JoPPClyeG8zxyOLx8W0mGNrwLFO4ugBSzwz-WxSl2Fi10Z3luNSi_YYDbqdl8ceqdooEM39OCdp7GWBzzLgSmFK_UhRkTmRHeWlUjEhM9ccwvWgjnlsmIy00jpkkkU0g99U8RPUsBNrzhD2Y9h_ZIIZyaSjgjGjOgyDWAQ01R5VTXRbWzOZLtUykrUusrN9ArZPStsniyZq1QZPqi9nnnAvErRUpmui69XfEPMukSGtmRRuDEQYIIfP_xgDUB5SYJtBE50unbmaEpA0gDF3913t3fUEfp_v-f-GX6BdVkaaOy3YQo18VphLYDC5uioD9hMe5Oeb
  priority: 102
  providerName: Springer Nature
Title Exostosin-1/exostosin-2 expression and favorable kidney outcomes in lupus nephritis: a retrospective cohort study
URI https://link.springer.com/article/10.1007/s10067-024-07043-x
https://www.ncbi.nlm.nih.gov/pubmed/38922553
https://www.proquest.com/docview/3084100118
https://www.proquest.com/docview/3072296353
https://www.proquest.com/docview/3153711636
Volume 43
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9NAEF_0DsQX8dvqeazgmy6X_Ug28UVaaT2UKyIW6lPYr8DhkfTaROp_70y6aZHDe9pANrDMTGZ_uzPzG0LeAmATzmWeSeUkU6mtmFGJYZmVyvLEaNkXCl_Ms_OF-rJMl_HCbRPTKgef2Dtq3zi8Iz-TSa54z1j2cXXNsGsURldjC4275BipyzClSy_3By4MovUd87RGX1PksWgmls6Bn2awQzEweiXZ9t-N6QbavBEp7Teg2UPyICJHOt6p-hG5E-rH5N5FjI0_IdfTLZJkwNmf8bOwfxY0bGOya01N7WllfoPa7VWgvy59Hf7QpmtBBGFDL2t61a26Da0DqBjJjj5QQ9ehXTdDQSbFhrrrlvastE_JYjb98emcxYYKzMm0aJkvkipLRQWoSXue5parCul2bOKNFcpU2CYCu1EXsgjC5M46p4UROa9g9FY-I0d1U4cXhKYFnEQqJYIRBkFhIbjTOitUxr1LuB2Rd4M0y9WON6M8MCSj7EuQfdnLvtyOyMkg8DL-Q5vyoPERebN_DdaPIQ1Th6bDOWBr4ENSecsccOqaA-7MRuT5Tpn7JQFcA4eGX78ftHtYwP_X-_L29b4i90VvWZgneEKO2nUXXgN2ae1pb6Cn5Hg8m0zmOH7--XUK42Q6__Yd3i7E-C-YgO-t
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9RAEB_qFdQX8dvTqivoky7NfuRLEPHjytX2DpEW-pbubjZwWDbXS6LXf8q_0dlccocU-9anBLIJy-xvZn6b2ZkBeI2EjRsT5VRII6gMdUGVDBSNtJCaBSoWbaLwZBqNj-W3k_BkC_70uTD-WGVvE1tDnZfG_yPfFUEiWVux7OP8nPquUT662rfQWMHiwF78xi1b9WH_K67vG873RkdfxrTrKkCNCNOa5mlQRCEvkDrEOQsTzWTha87oIFeaS1X4Xgm-JXMqUstVYrQxMVc8YQVecy3wuzdgWwrcygxg-_No-v3H2vbzrkdfHHvrliZdmk6XrIeegaJPpKhmUtDlv67wEr-9FJttXd7eXbjTcVXyaQWue7Bl3X24Oemi8Q_gfLT0ZTmqmaNs167vObHL7nitI8rlpFC_EGj6zJKfs9zZC1I2NQrdVmTmyFkzbyriLILKl1d6TxRZ2HpR9imgxLfwXdSkrYP7EI6vRdiPYOBKZ58ACVPc-xSSW8WVp6EpZyaOo1RGLDcB00N420szm68qdWSbmsxe9hnKPmtlny2HsNMLPOu0tso2GBvCq_Vj1DcfRFHOlo0fg-hGqxWKK8agG4kZMt1oCI9Xi7meEhJENKH-7Xf96m4m8P_5Pr16vi_h1vhocpgd7k8PnsFt3qLMn1LcgUG9aOxzZE61ftHBlcDpdWvIX-THJ6g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9RAFD7UCsUX8d7VqiPokw6buSSTCCJiu7TWFh8s7FucmUxgsUy2m0S3f81f55lssosU-9anBDIJhzPn8k3ODeA1AjZubVJQIa2gMjYl1TLSNDFCGhZpJbpC4ZPT5PBMfpnG0y34M9TChLTKwSZ2hrqobPhHPhZRKlnXsWxc9mkR3_YnH-cXNEyQCpHWYZzGSkSO3eVvPL7VH472ca_fcD45-P75kPYTBqgVcdbQIovKJOYlwghVsDg1TJah_4yJCm241GWYmxDGM2cic1yn1liruOYpK_FaGIHfvQW3lYhZ0DE1XR_2QgCvm9anVLBzWdoX7PRle-gjKHpHigonBV3-6xSvIN0rUdrO-U3uwd0etZJPKzG7D1vOP4Cdkz4u_xAuDpahQUc985SN3fqeE7fsE2090b4gpf6FImfOHfk5K7y7JFXbIPtdTWaenLfztibeoXiFRkvviSYL1yyqoRiUhGG-i4Z0HXEfwdmNsPoxbPvKu10gcYanoFJyp7kOgDTjzCqVZDJhhY2YGcHbgZv5fNWzI990Zw68z5H3ecf7fDmCvYHhea-_db6RthG8Wj9GzQvhFO1d1YY1KOdov2JxzRp0KIoh5k1G8GS1mWuSECqiMQ1vvxt2d0PA_-l9ej29L2EH9SL_enR6_Azu8E7IQrriHmw3i9Y9RwjVmBedrBL4cdPK8Rebcip4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Exostosin-1%2Fexostosin-2+expression+and+favorable+kidney+outcomes+in+lupus+nephritis%3A+a+retrospective+cohort+study&rft.jtitle=Clinical+rheumatology&rft.au=Zavala-Miranda%2C+Maria+Fernanda&rft.au=Sobrino-Vargas%2C+Ana+Mar%C3%ADa&rft.au=Hern%C3%A1ndez-Andrade%2C+Adriana&rft.au=Caballero-Malacara%2C+Valeria&rft.date=2024-08-01&rft.pub=Springer+Nature+B.V&rft.issn=0770-3198&rft.eissn=1434-9949&rft.volume=43&rft.issue=8&rft.spage=2533&rft.epage=2540&rft_id=info:doi/10.1007%2Fs10067-024-07043-x&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0770-3198&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0770-3198&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0770-3198&client=summon